Coeurative

Executive Summary

Coeurative is a preclinical-stage biotechnology company focused on developing novel therapies for coronary artery disease (CAD) and its primary symptom, angina pectoris. The company's lead candidate, CR-0305, is a first-in-class small molecule designed to provide both immediate symptom relief and long-term vascular benefits. It specifically targets patients with Ischemia with Non-Obstructive Coronary Arteries (INOCA) and refractory angina, conditions with limited treatment options. Founded in 2021 and headquartered in San Diego, Coeurative aims to address a critical unmet need in cardiovascular medicine. The market opportunity for CR-0305 is significant, as INOCA affects approximately 3-4 million patients in the US alone, and refractory angina impacts a growing population with advanced CAD. Current therapies focus on symptom management and do not address underlying vascular dysfunction. CR-0305's dual mechanism could differentiate it from existing treatments, offering both acute relief and disease modification. As a Phase 1-stage asset, CR-0305 faces typical early-stage development risks, including safety, efficacy, and funding hurdles. However, the strong scientific rationale and clear patient need position Coeurative as a compelling opportunity in the cardiovascular space.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Safety and PK Data Readout70% success
• Q3 2026Series A Financing Announcement60% success
• Q1 2027IND Submission for Next Indication (e.g., stable angina)50% success